Citigroup Maintains Buy on Bioage Labs, Lowers Price Target to $20

Benzinga · 1d ago
Citigroup analyst Samantha Semenkow maintains Bioage Labs (NASDAQ:BIOA) with a Buy and lowers the price target from $21 to $20.